Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 23;19(1):134.
doi: 10.1186/s12969-021-00613-2.

Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: A retrospective study, JUPITER

Sezgin Sahin  1 , Ceyhun Acari  2 , Hafize Emine Sonmez  3 , Fatma Zehra Kilic  4 , Erdal Sag  3 , Hatice Adiguzel Dundar  2 , Amra Adrovic  1 , Selcan Demir  3 , Kenan Barut  1 , Yelda Bilginer  3 , Betul Sozeri #  4 , Erbil Unsal #  2 , Seza Ozen #  3 , Ozgur Kasapcopur #  5
Affiliations

Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: A retrospective study, JUPITER

Sezgin Sahin et al. Pediatr Rheumatol Online J. .

Abstract

Background: Juvenile idiopathic arthritis (JIA), is the most common pediatric rheumatologic disorder with unknown etiology. Currently, no population-based data are available regarding the distribution of categories and frequency of uveitis in patients with JIA in Turkey. The purpose of this study was to evaluate the frequency of JIA-associated uveitis (JIAU) and distribution of JIA categories in a Turkish JIA cohort.

Methods: This was a retrospective study of 500 randomized patients in four pediatric rheumatology clinics in Turkey.

Results: Oligoarticular JIA (oJIA) was the most common JIA disease category in this study cohort (38.8%). The frequencies of the other categories were as follows: enthesitis-related arthritis (ERA), 23.2%; rheumatoid factor (RF)-negative polyarthritis, 15.6%; systemic arthritis, 12.2%; juvenile psoriatic arthritis, 5.2%; undifferentiated arthritis, 2.8%; and RF-positive polyarthritis, 2.2%. JIA-associated uveitis was observed in 6.8% of patients at a mean (Standard Deviation, SD) age of 9.1 (3.8) years over a mean JIA disease duration of 4 (1.9) years. Uveitis developed after joint disease, with a mean (SD) duration of 1.8 (1.9) years. Patients with oJIA had the highest rate of uveitis (12.9%) followed by patients with ERA (5.2%) and polyarticular RF-negative disease (3.8%). Compared with persistent oJIA, the extended oJIA category had a > 3-fold higher risk of uveitis (11.3% vs 27.7%; odds ratio, 3.38 [95% Confidence Interval, 1.09-10.4]). The most frequently administered drug after development of uveitis was tumor necrosis factor-alpha inhibitors (38.2%). Five patients (14.7%) had uveitis-related complications that required surgical intervention.

Conclusions: Turkish pediatric patients with JIA experience a lower frequency of oJIA and higher frequency of ERA than their white European counterparts; the occurrence of uveitis is also somewhat lower than expected. Geographic and ethnic factors may affect these differences and need further investigation.

Keywords: ANA; Frequency; HLA-B27; Juvenile idiopathic arthritis; Turkey; Uveitis.

PubMed Disclaimer

Conflict of interest statement

S.S. received a research grant from AbbVie.

C.A. received a research grant from AbbVie.

H.E.S. received a research grant from AbbVie.

F.Z.K. received a research grant from AbbVie.

E.S. received a research grant from AbbVie.

H.A.D. received a research grant from AbbVie.

A.A. received a research grant from AbbVie.

S.D. received a research grant from AbbVie.

K.B. received a research grant from AbbVie.

Y.B. received a research grant from AbbVie.

B.S. received research grant, consulting fee and/or speaker fee from AbbVie, Pfizer, Roche, Novartis, and Celltrion.

E.U. received research grant and consulting fee from Novartis, AbbVie, Roche, and Kocak Pharma.

S.O. received research grant and consulting fee from Novartis and speaker fee from Roche and SOBI.

O.K. received a research grant from AbbVie.

Figures

Fig. 1
Fig. 1
The comorbid conditions observed in the JUPITER cohort
See this image and copyright information in PMC

References

    1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392. - PubMed
    1. Barut K, Adrovic A, Şahin S, Kasapçopu Ö. Juvenile idiopathic arthritis. Balkan Med J. 2017;34(2):90–101. doi: 10.4274/balkanmedj.2017.0111. - DOI - PMC - PubMed
    1. Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: A systematic review. Joint Bone Spine. 2014;81:112–117. doi: 10.1016/j.jbspin.2013.09.003. - DOI - PubMed
    1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–2149. doi: 10.1016/S0140-6736(11)60244-4. - DOI - PubMed
    1. Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol. 2015;11(6):338–348. doi: 10.1038/nrrheum.2015.20. - DOI - PubMed

MeSH terms

Substances